Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 8,610 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Disorder Clear all
Completed Phase 1 Interventional

A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV

NCT00001049
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 3 Months
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

NCT03760458
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets, Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 11 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

NCT05281263
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
CPI-RSV-F Vaccine (BLB-201)
Biological
Lead sponsor
Blue Lake Biotechnology Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Cincinnati, Ohio • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

NCT00294047
View directory record Official record
Conditions
Infections, Papillomavirus, Papillomavirus Vaccines
Interventions
Cervarix, Placebo control
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
26 Years and older · Female only
Enrollment
5,752 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
36
States / cities
Fountain Valley, California • Aurora, Colorado • Golden, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 21, 2026, 11:14 PM EDT
Completed No phase listed Observational

A Registry of Tuberculosis Cases in the CPCRA

NCT00000785
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day and older
Enrollment
1,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1994
U.S. locations
13
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1 Interventional

A Study of MDL 28,574A in HIV-Infected Patients

NCT00002329
View directory record Official record
Conditions
HIV Infections
Interventions
Celgosivir hydrochloride
Drug
Lead sponsor
Hoechst Marion Roussel
Industry
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions

NCT01132729
View directory record Official record
Conditions
Herpes Zoster, Shingles, Genital Herpes
Interventions
Valacyclovir Hydrochloride
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 21, 2026, 11:14 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

NCT03160339
View directory record Official record
Conditions
Adenoviral Infection
Interventions
PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Cincinnati, Ohio • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 21, 2026, 11:14 PM EDT
Not yet recruiting Phase 2 Interventional

A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size

NCT07881809
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus)
Interventions
Ixazomib 4 mg, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 11:14 PM EDT
Completed No phase listed Observational

Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF

NCT01832519
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 52 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Not applicable Interventional

A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons

NCT00002130
View directory record Official record
Conditions
HIV Infections
Interventions
Vesnarinone
Drug
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 11:14 PM EDT
Recruiting Phase 1 Interventional

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

NCT05849467
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
Interventions
89 Zr-Df-crefmirlimab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 11:14 PM EDT
Terminated Phase 3 Interventional Results available

Empiric Therapy of Mucopurulent Cervicitis (MPC)

NCT01072136
View directory record Official record
Conditions
Vaginitis Bacterial, Cervicitis
Interventions
Placebo, Azithromycin, Cefixime
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Birmingham, Alabama • Torrance, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 4 Interventional Results available

Effect of Methamphetamine on Residual Latent HIV Disease Study

NCT03825536
View directory record Official record
Conditions
HIV-1-infection, Methamphetamine-dependence
Interventions
Oral Methamphetamine, Placebo oral capsule
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 2 Interventional

A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3

NCT00000771
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Paromomycin sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
14
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

NCT05819398
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab i.v., Spesolimab s.c., Placebo matching Spesolimab i.v., Placebo matching Spesolimab s.c.
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1Phase 2 Interventional

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

NCT00029328
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
Interventions
etanercept
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
12 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine

NCT00000628
View directory record Official record
Conditions
HIV Infections
Interventions
L-697,661, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of the Vaginal Gel PRO 2000/5

NCT00006207
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 2000
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 21, 2026, 11:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs

NCT00017771
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Results available

PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection

NCT03239899
View directory record Official record
Conditions
HIV Infections
Interventions
Pembrolizumab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 21, 2026, 11:14 PM EDT
Completed No phase listed Observational

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

NCT03399981
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy
Interventions
Tysabri
Biological
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
80,327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 3 Interventional

Vaginal Infection Study 2

NCT00694928
View directory record Official record
Conditions
Vaginal Infection
Interventions
clindamycin phosphate/butoconazole nitrate, butoconazole nitrate
Drug
Lead sponsor
Lumara Health, Inc.
Industry
Eligibility
16 Years and older · Female only
Enrollment
843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Birmingham, Alabama • Montgomery, Alabama • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 2 Interventional

A Study of Azidothymidine in HIV-Infected Children

NCT00000982
View directory record Official record
Conditions
Encephalopathies, HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 21, 2026, 11:14 PM EDT